Oculus Innovative Sciences Launches Microcyn(R) Negative-Pressure Wound Therapy Solution for U.S. Market

Microcyn NPWT Solution to Be Showcased at Both the New Cardiovascular Horizons Conference in New Orleans June 1-5 and the WOCN Conference in Phoenix June 12-16

PETALUMA, Calif.--(BUSINESS WIRE)-- Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn(R) Technology platform, today introduced the Microcyn Negative-Pressure Wound Therapy Solution(TM) for the U.S. professional healthcare market. Within the pH ranges of 6-7.8 desired for optimum negative-pressure wound therapy, Microcyn is intended for the irrigation and management of wounds via these advanced systems.

Tom Wolvos, M.D., F.A.C.S. of Scottsdale Surgical Consultants in Arizona, a major proponent of negative-pressure wound therapy who has published multiple peer-review studies on NPWT, said: "From my personal experience, the Microcyn Technology, with its proven safe-as-saline profile and unmatched efficacy, is an optimum irrigation solution for use with the ten plus negative-pressure wound therapy systems on the market today, including Kinetic Concept's V.A.C. Instill(R). Microcyn's ability to safely eradicate bacteria, fungi and spores in-solution without facilitating resistance truly sets it apart from other solutions in this space. And the fact it has no known drug or treatment contraindications makes it an easy and cost-efficient choice since Microcyn is compatible with the dressings and systems used for negative-pressure wound therapy with irrigation."

The Microcyn Negative-Pressure Wound Therapy Solution, available in both 500 mL and 990 mL spikeable pharmasling(R) bottles, is being marketed in the United States via Oculus' 60-person commission-based sales force. For more information, pricing or ordering visit http://store.oculusis.com/ or phone 1-800-931-3205.

About Oculus Innovative Sciences

Oculus Innovative Sciences is a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn(R) Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing. The Microcyn Technology addresses the need for improved solutions in multiple markets including dermatology, oral care, cosmeceutical, wound care and others. It features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries under various country specific regulatory clearances and approvals. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores; increase blood flow to the wound site, and reduce both inflammation and pain while assisting in faster wound closure. The company's headquarters are in Petaluma, California, with operations in Latin America. More information can be found at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the Company's commercial and technology progress and future financial performance. These forward-looking statements are identified by the use of words such as "marketed," "launches," and "showcased," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year ended March 31, 2009. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements except as required by law.

Oculus, Microcyn Negative-Pressure Wound Therapy Solution and Microcyn Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

Editor Note: High-resolution product photos available upon request.

    Source: Oculus Innovative Sciences, Inc.

Released June 2, 2010